IN8BIO, INC. (INAB)
$1.04+$0.00 (+0.34%) Today
Latest INAB Insider Trades
Leslie W. Kreis - 10% OwnerOpen-market purchase709,040 sh
Leslie W. Kreis - 10% OwnerLeslie W. Kreis - 10% Owner
Emily Fairbairn
William Tai-Wei Ho - Officer
Luba GreenwoodIN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
No Form 4 activity for INAB in the last 90 days.
33 Form 4 filings on record, the earliest from Oct 8, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Patrick McCall - Officer | Grant or award | Common Stock | 25,316 | - | - | |
| Patrick McCall - Officer | Derivative | Series A Warrants (right to buy) | 20,492 | - | - | |
| Patrick McCall - Officer | Grant or award | Series A Warrants (right to buy) | 20,492 | - | - | |
| Patrick McCall - Officer | Grant or award | Series C Warrants (right to buy) | 25,316 | - | - | |
| Emily Fairbairn | Open-market purchase | Series C Warrants (right to buy) | 3,038,743 | - | - | |
| Emily Fairbairn | Open-market purchase | Pre-Funded Warrants (right to buy) | 3,038,743 | - | - | |
| Alan S. Roemer | Grant or award | Common Stock | 126,582 | - | - | |
| Alan S. Roemer | Derivative | Series A Warrants (right to buy) | 102,459 | - | - | |
| Alan S. Roemer | Grant or award | Series A Warrants (right to buy) | 102,459 | - | - | |
| Alan S. Roemer | Grant or award | Series C Warrants (right to buy) | 126,582 | - | - |
This is as far as the anonymous view goes. Create a free account for all 33 INAB filings on record.
IN8BIO, INC. (INAB) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-29. The full record for INAB runs to 33 Form 4 filings, the earliest from 2024-10-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of INAB were filed in the last 90 days. 6 purchases are on record for this company.
No insider sales of INAB were filed in the last 90 days.
This page tracks INAB Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add INAB to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
